Hemorrhage Clinical Trial
Official title:
Thromboelastometry as a Tool to Predict Bleeding and Transfusion Requirement During Liver Transplantation
Patients with cirrhosis present complex coagulation defects. Conventional coagulation tests (INR, platelets count) can not predict bleeding or blood product requirements during liver transplantation. Thromboelastometry (TEM)analyser measures the viscoelastic of the whole blood coagulation generation and lysis. TEM results are available more rapidly than conventional tests and give additional information regarding coagulation strengh, platelet function, and fibrinolysis.
Historically, orthotopic liver transplantation (OLT) has been associated with major blood
loss and the need for massive blood product transfusion . The cause of bleeding during OLT is
multifactorial . The extensive surgical trauma plays a major role in the origin of bleeding.
This bleeding can be accelerated by defects of the hemostatic system. Hemostatic defects can
be divided into those present before the operation and those originating during the surgery.
The latter can be classified according to the 3 main systems of hemostasis: coagulation,
platelet function, and fibrinolysis. Hyperfibrinolysis is an important cause of non surgical
bleeding during OLT .
A significant decrease in blood loss and blood product requirements has been observed during
OLT over the past 10 years . This decrease can be explained by increase experience,
improvements in surgical and anesthetic techniques, and a better understanding of the various
hemostatic abnormalities encountered during OLT.
More than 10 years ago, Reyle-Hahn and Rossaint and Dupont et al stated that it is not
necessary to correct coagulation defects before the anhepatic phase. More recently, some
authors have a poor correlation between bleeding and the peripheral indices of coagulation in
patients with chronic liver disease . These patients with cirrhosis are investigated by means
of conventional tests for coagulation and primary hemostasis such as prothrombin time (INR),
activated partial thromboplastin time (aPTT), platelet count, and skin bleeding time. Two
important studies have raised serious questions about clinical use of INR in both measuring
liver disease prognosis and in estimating bleeding risk thus calling into question many
common and traditional clinical practices .
Now, it is cleat that conventional tests of coagulation (INR, platelet count, fibrinogen) are
not able to predict blood product transfusion requirements and bleeding during liver
transplantation.
A substantial body of evidence suggests that the use of blood products is associated with
morbidity and mortality . Because 33% of liver recipients had acquired their liver disease
through the transfusion of blood products , it is important to establish strategies aimed at
decreasing blood losses and consequently the need for transfusion. The ability to predict
intraoperative blood loss and transfusion requirements would be of great help to ensure
adequate blood products and to enable appropriate therapy for patients at high risk of
bleeding.
The ROTEM (TEM) thromboelastometry analyzer based on throboelastographic principles ,
measures the viscoelastic properties of whole blood coagulation generation and lysis. The
instrument provides important global hemostatic information about the
plasma-platelet-leucocyte interaction and clot tensile strength . TEM results are available
more rapidly than those from laboratory-based conventional coagulation testing and also
provide additional information regarding coagulation strength, platelet function, and
fibrinolysis. Kang et al 39 using thromboelastogram (TEG) showed a decrease in red blood
cells (RBC) use after the introduction of TEG monitoring.
ROTEM analysis includes plasmatic coagulation and fibrinolytic factors and inhibitors, as
well as all circulating blood cells and provides clinically important information about
quality of the final blood clot.
The aim of this observational study was to determine if ROTEM parameters were able to predict
blood losses and transfusion of RBC during a liver transplantation.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02815670 -
Reversal Dabigatran Anticoagulant Effect With Idarucizumab
|
Phase 3 | |
| Completed |
NCT04588350 -
Clinical Investigation Evaluating a New Autotransfusion Device in Cardiac Surgery
|
N/A | |
| Recruiting |
NCT02972385 -
Pharmacogenomics of Warfarin in Hispanics and Latinos
|
||
| Completed |
NCT02554006 -
Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings
|
N/A | |
| Completed |
NCT02569606 -
Transfusion and Coagulation Management in Trauma Patients After the Introduction of a Coagulation Algorithm
|
||
| Recruiting |
NCT02446730 -
Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome
|
Phase 4 | |
| Completed |
NCT01955720 -
Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran
|
Phase 1 | |
| Completed |
NCT01935427 -
Comparison of Compensatory Reserve Index to Intravascular Volume Change and Stroke Volume
|
N/A | |
| Recruiting |
NCT01709786 -
Non-Invasive Hemoglobin Monitoring in Patients With Hemorrhage
|
N/A | |
| Completed |
NCT01191554 -
Dose-ranging Study of Tranexamic Acid in Valve Surgery
|
N/A | |
| Completed |
NCT01210417 -
Trauma Heart to Arm Time
|
N/A | |
| Completed |
NCT01136590 -
Multicenter, Randomized Placebo-controlled Clinical Trial to Evaluate the Effect of Perioperative Use of Tranexamic Acid on Transfusion Requirements and Surgical Bleeding in Major Spine Surgery
|
Phase 4 | |
| Completed |
NCT01085006 -
The Effect of Tranexamic Acid on Postpartum Hemorrhage During and After Cesarean Delivery
|
Phase 1/Phase 2 | |
| Completed |
NCT00700141 -
Non-Interventional Study About Treatment of Hemorrhages in Thyroid Surgery With TachoSil®
|
N/A | |
| Completed |
NCT00375466 -
Tranexamic Acid, Hemorrhage and Transfusions After Combined Aortic Valve Replacement and Coronary Artery Bypass Surgery.
|
N/A | |
| Completed |
NCT00147420 -
RCT of Zhi Byed 11 (ZB11) Versus Misoprostol in Tibet
|
N/A | |
| Completed |
NCT00479362 -
Anticoagulant Therapy During Pacemaker Implantation
|
Phase 4 | |
| Recruiting |
NCT05945680 -
Tranexamic Acid in Breast Esthetic Surgery.
|
Phase 4 | |
| Completed |
NCT03273322 -
Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT05672407 -
The Role of Local Tranexamic Acid on Periorbital Oculoplastic Surgery
|
Phase 4 |